NCT06443489RecruitingPhase 1
A Phase I ,Open-label, Multicenter Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics and Efficacy of SHR-4849 in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.1 site in 1 country80 target enrollmentStarted: June 26, 2024Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- MTD or MAD：after all subjects of dose escalation phase be enrolled，and all subjects complete at least one cycle of dosing observation.
Study Overview
Brief Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection in Advanced Solid Tumors. To explore the reasonable dosage of SHR-4849 for Advanced Solid Tumors.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject has provided informed consent prior to initiation of any study-procedures
- •Age from 18 to 75 years old at the time of signing the informed consent
- •Histologically or cytologically confirmed advanced solid tumors
- •At least one measurable lesion was identified per RECIST 1.1
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •Has a life expectancy of at least 3 months.
- •Adequate organ function
- •Subjects of both genders of child-bearing potential were required to use highly effective contraception from the time they provided written informed consent until 6 months after the last dose of the trial drug
Exclusion Criteria
- •Subjects with active central nervous system (CNS) metastasis.
- •Subjects with a history of malignant tumors within 5 years prior to the first dose
- •Subjects with uncontrolled cancer pain.
- •Subjects with severe cardiovascular disease.
- •Subjects with clinically significant hemorrhage
- •Subjects with uncontrolled pleural effusion, peritoneal effusion and pericardial effusion
- •Subjects highly suspected of interstitial lung disease
- •Subjects with serious infection within 4 weeks prior to the first dose
- •Known history of human immunodeficiency virus (HIV)，active hepatitis B virus or hepatitis C virus infection.
- •The adverse events of previous antineoplastic therapy did not recover to NCI-CTCAE≤ grade 1
- •Subjects who received anti-cancer treatment within 4 weeks prior to the first dose
- •Subjects who received major surgery within 4 weeks prior to the first dose
- •Subjects who plan to receive or have received live vaccines within 28 days prior to the first dose.
- •Female subjects who were pregnant, lactating, or planned to become pregnant during the study period
- •Known allergic to any component of SHR-4849 products
- •Alcohol abuse, drug abuse, other serious medical conditions (including mental illness) requiring combined treatment, and other conditions that may affect subject safety or data collection.
- •Based on the investigator's judgment, subjects with other conditions that may affect study results, interfere with study procedures,
Arms & Interventions
SHR-4849
Experimental
Intervention: SHR-4849 (Drug)
Outcomes
Primary Outcomes
MTD or MAD：after all subjects of dose escalation phase be enrolled，and all subjects complete at least one cycle of dosing observation.
Time Frame: up to 24 months
DLT：the incidence of events associated with the investigational drug determined by the investigator during the observation period
Time Frame: up to 21 days
Incidence and severity of AE/SAE：According to NCI-CTCAE v5.0 evaluation criteria, from the signing of informed consent to the end of safety follow-up；
Time Frame: up to 24 months
RP2D：after all subjects of dose escalation and dose expansion phase be enrolled，and all subjects complete at least one cycle of dosing observation.
Time Frame: up to 24 months
Secondary Outcomes
- OS: Overall Survival . Defined as the time from the initiation of the first medication to death from any cause.(up to 30 months)
- ORR： Objective Response Rate (ORR) as Assessed by investigators. The proportion of subjects whose best response was PR or CR according to RECIST1.1(up to 24 months)
- DCR：Disease Control Rate(DCR) as Assessed by investigators. the proportion of subjects whose best response was PR or CR or SD according to RECIST1.1(up to 24 months)
- DoR: Duration of Response (DOR) as Assessed by investigators according to RECIST1.1, Defined as the period of time from the first documented tumor response to the first documented objective progression or death of any cause.(up to 24 months)
- PFS: Progression-free Survival (PFS) as Assessed by investigators according to RECIST1.1. Defined as the time from the initiation of the first medication to tumor progression or death from any cause (whichever comes first)；(up to 24 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Study of SHR-4375 in Subjects With Solid TumorsSolid TumorsNCT06764628Suzhou Suncadia Biopharmaceuticals Co., Ltd.208
Completed
Phase 1
A Study of SHR4010 in Patients With HemodialysisPruritusNCT04099927Jiangsu HengRui Medicine Co., Ltd.12
Recruiting
Phase 1
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal AdenocarcinomaPancreatic CancerNCT06427239Fudan University130
Recruiting
Phase 1
A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.Breast CancerNCT05845138Suzhou Suncadia Biopharmaceuticals Co., Ltd.116
Active, not recruiting
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy SubjectsPrevention of Arterial and Venous ThrombosisNCT05369767Beijing Suncadia Pharmaceuticals Co., Ltd64
Related News
FDA Clears IND for IDEAYA's Novel DLL3-Targeting Antibody Drug Conjugate IDE849 for Solid Tumors- IDEAYA Biosciences has received FDA clearance for a Phase 1 clinical trial of IDE849, a potential first-in-class DLL3-targeting Topo-I-payload antibody drug conjugate for solid tumors including small cell lung cancer and neuroendocrine tumors.
- The ongoing Phase 1 study by partner Hengrui Pharmaceuticals has already demonstrated multiple partial responses at therapeutic dose levels with predominantly Grade 1-2 adverse events and no drug-related discontinuations reported.
- IDEAYA plans to evaluate IDE849 both as monotherapy and in combination with their PARG inhibitor IDE161, with clinical data from over 40 SCLC patients expected to be presented at a medical conference in Q3 2025.last yearIDEAYA Biosciences Licenses DLL3-Targeting ADC from Hengrui Pharma in $1B Deal• IDEAYA Biosciences has secured an exclusive license from Hengrui Pharma for SHR-4849, a DLL3-targeting antibody-drug conjugate (ADC), outside of Greater China.
• SHR-4849 is currently in Phase 1 trials and has demonstrated promising antitumor activity in preclinical studies, particularly in small cell lung cancer (SCLC).
• The agreement includes a $75 million upfront payment to Hengrui, with potential milestone payments reaching up to $1.045 billion, plus royalties on net sales.
• IDEAYA plans to file a US IND for SHR-4849 in the first half of 2025, with potential for combination therapies with its PARG inhibitor IDE161.last year